Kazia CEO, Dr James Garner was recently featured on Stockhead’s new podcast series, “The Health Kick Podcast” with Tim Boreham.
In the interview, Dr Garner discusses:
- The company’s journey from Novogen to Kazia and building a world-class, 21st century drug developer
- Kazia’s recent achievements and milestones, including the company’s win of an inaugural ANZLF Trans-Tasman Innovation and Growth Award
- The blood brain barrier and how Kazia’s lead candidate, GDC-0084, treats glioblastoma, the most aggressive form of brain cancer
Kazia will be presenting at the upcoming Australia Biotech Invest & Partnering conference on Thursday 31 October at the Melbourne Convention and Exhibition Centre.
For more information on Kazia register your interest below.